ArticleJCO oncology practice2021
Out-of-Pocket Costs for Tyrosine Kinase Inhibitors and Patient Outcomes in
Article in JCO oncology practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impacts of National Reimbursement Drug Price Negotiation on drug accessibility, utilization, and cost in China: a systematic review.International journal for equity in health · 2025Pooled it
- The Efficacy of Adjuvant EGFR-TKI Therapy for Stage IA Lung Adenocarcinoma with EGFR Mutations: A Retrospective Cohort Study.Annals of surgical oncology · 2026Article
- Maintenance Liposomal Doxorubicin Following Induction Doxorubicin in Soft Tissue Sarcoma: A Single-Center Observational Study.Current oncology (Toronto, Ont.) · 2026Observational
- Review
- Screening for comprehensive social needs in patients with cancer: a narrative review.JNCI cancer spectrum · 2025Review
- Proceedings of the 1st biannual bridging the gaps in lung cancer conference.The oncologist · 2025Article
- Preferences for public health insurance coverage of new anticancer drugs: a discrete choice experiment among non-small cell lung cancer patients in China.BMC public health · 2025Article
- Development of Item Banks to Assess Financial Hardship in Cancer Survivors Using Item Response Theory.Frontiers in cancer control and society · 2025Article
- Addressing financial hardship in malignant hematology and hematopoietic cell transplant: a team approach.Blood advances · 2024Article
- Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy.JNCI cancer spectrum · 2024Article
- Association between oral targeted cancer drug net health benefit, uptake, and spending.Journal of the National Cancer Institute · 2024Article
- Financial hardship after cancer: revision of a conceptual model and development of patient-reported outcome measures.Future science OA · 2024Article
- Association of financial worry with substance use, mental health, and quality of life in cancer patients.Journal of cancer survivorship : research and practice · 2023Article
- Modeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Non-Small-Cell Lung Cancer in the United States.JCO precision oncology · 2023Article
- Predictors of adherence to oral anticancer medications: An analysis of 2010-2018 US nationwide claims.Journal of managed care & specialty pharmacy · 2022Article
- Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma.Journal of geriatric oncology · 2022Article
- Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023?Expert opinion on therapeutic targetsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeWe investigated the association of out-of-pocket (OOP) costs for tyrosine kinase inhibitors (TKIs) with overall survival (OS) in epidermal growth factor receptor (
methodsWe used the Hutchinson Institute for Cancer Outcomes Research registry-claims database to identify patients with stage IV
resultsSeventy-eight and twenty-seven patients comprised the Q1-3 and Q4 groups, respectively. Median monthly TKI OOP costs were $1,431 (Q1-3)
conclusionAmong patients with advanced
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.